Fig. 1.
Bibliometric variables
| Number of articles (%) | |
|---|---|
| Year of publication | |
| 2010–2014 | 4(17,4) |
| 2015–2019 | 10(43,5) |
| 2020–2023 | 9(39,1) |
| Country of publication | |
| United States | 8(34,8) |
| United Kingdom | 6(26,1) |
| Switzerland | 2(8,7) |
| Others | 7(30,4) |
| Study design | |
| Review | 1(4,4) |
| Observational | 17(73,9) |
| Experimental | 5(21,7) |
| Ventilatory strategies | |
| Conventional oxygen therapy | 3(13,1) |
| High Flow Nasal Cannula | 2(8,7) |
| Non-invasive ventilation | 7(30,4) |
| Invasive ventilation | 17(73,9) |
| Combination of strategies | 4(17,3) |
Report of ventilatory record
| Number of articles (%) | |
|---|---|
| Coexistence of ventilatory strategies | 5 (22) |
| PEEP evaluation | 16 (70) |
| Evaluation/record of pulmonary mechanic parameters | 11 (48) |
| Report of the time of use of each strategy | 21 (91) |
| Report of intervention with Oxygen therapy | 13 (57) |
| Report of prone position as a non-ventilatory strategy | 9 (39) |
j_jccm-2025-0019_tab_004
| Data bases | Key words combination | Articles retrieved |
|---|---|---|
| Pubmed 20/10/2023 15h47 UTC+2 | (((“Adult”[Mesh] OR “Adult” OR “Patients”[Mesh] OR “Patients”) AND (“Intensive Care Units”[Mesh] OR “Intensive Care Units”) AND (“Respiratory Distress Syndrome”[Mesh] OR “Respiratory Distress Syndrome” OR “Acute Respiratory Distress Syndrome” OR “ARDS”)) AND ((“Respiratory Therapy”[Mesh] OR “Respiratory Therapy” OR “Respiration, Artificial”[Mesh] OR “Respiration, Artificial”) OR (“Therapeutics”[Mesh] OR “Therapeutics”) OR “Treatment” OR (“Noninvasive Ventilation”[Majr] OR “Noninvasive Ventilation” OR “Intubation, Intratracheal”[Majr] OR “Intubation, Intratracheal” OR “Intubation”[Mesh] OR “Endotracheal Intubation” OR “High Flow Nasal Canula” OR “HFNC” OR “High Flow Oxygen Therapy” OR “HFOT”)) AND (“Time”[Mesh] OR “Time” OR “Timing” OR “Time-to-Treatment”[Mesh] OR “Time-to-Treatment” OR “Time Management”[Mesh] OR “Time Management”)) [FILTERS: 10 YEARS - HUMAN - ADULTS +19] | 297 |
| Science direct 25/10/2023 18h49 UTC+2 | “intensive care unit” AND (“Acute Respiratory Distress Syndrome” OR “ARDS”) AND (“Ventilation” OR Noninvasive Ventilation OR Intubation OR “High Flow Nasal Cannula” OR High Flow Oxygen Therapy) AND time | 61 |
| Year(s): 2013–2023; research articles | ||
| EBSCO 26/10/2023 16h51 UTC+2 | (((“Adult”[Mesh] OR “Adult” OR “Patients”[Mesh] OR “Patients”) AND (“Intensive Care Units”[Mesh] OR “Intensive Care Units”) AND (“Respiratory Distress Syndrome”[Mesh] OR “Respiratory Distress Syndrome” OR “Acute Respiratory Distress Syndrome” OR “ARDS”)) AND ((“Respiratory Therapy”[Mesh] OR “Respiratory Therapy” OR “Respiration, Artificial”[Mesh] OR “Respiration, Artificial”) OR (“Therapeutics”[Mesh] OR “Therapeutics”) OR “Treatment” OR (“Noninvasive Ventilation”[Majr] OR “Noninvasive Ventilation” OR “Intubation, Intratracheal”[Majr] OR “Intubation, Intratracheal” OR “Intubation”[Mesh] OR “Endotracheal Intubation” OR “High Flow Nasal Canula” OR “HFNC” OR “High Flow Oxygen Therapy” | 79 |
| Academic search CINHAL Sportsdiscuss EJournals | ||
Reported outcomes from the selected articles
| Number of articles (%) | |
|---|---|
| Principal outcomes | |
| Reported ARDS severity level (PaO2/FiO2) | (30,4) |
| 14(61) | |
| ICU length of stay | 11(48) |
| ICU mortality | 10(43) |
| Duration of ventilation | 8(35) |
| Hospital length of stay | 8(35) |
| Follow-up mortality rate | 6(26) |
| Complications | 3(13) |
| Non-invasive ventilation failure | 6(26) |
| Hospital mortality | 14(61) |
| Other | |
| Secondary outcomes | |
| Temporality | 8(35) |
| Quality of life | 0(0) |
| Principal physiological outcomes | |
| PaO2/FiO2 | 19(83) |
| pH | 4(17) |
| SaO2 | 3(13) |
| PaO2 | 2(9) |
| PaCO2 | 3(13) |
| Bicarbonate | 2(9) |
| Lactate | 2(9) |
| Oxygen index | 2(9) |
| Other | 5(22) |